What is Ertensi?
Ertensi is used alone or together with other medicines to treat angina (chest pain) and high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Ertensi is a calcium channel blocker. It affects the movement of calcium into the cells of the heart and blood vessels. As a result, Ertensi relaxes blood vessels and increases the supply of blood and oxygen to the heart while reducing its workload.
Ertensi is available only with your doctor's prescription.
Ertensi indications
Hypertension: Ertensi is indicated for the first-line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. Patients not adequately controlled on a single antihypertensive agent may benefit from the addition of Ertensi, which has been used in combination with a thiazide diuretic, β-adrenoceptor-blocking agent or an angiotensin-converting enzyme inhibitor.
Ertensi is also indicated to reduce the risk of fatal coronary heart disease (CHD) and non-fatal myocardial infarction (MI), and to reduce the risk of stroke.
Coronary Artery Disease: Ertensi is indicated to reduce the risk of coronary revascularization and the need for hospitalization due to angina in patients with coronary artery disease (CAD).
Chronic Stable Angina: Ertensi is indicated for the first-line treatment of myocardial ischemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (Prinzmetal’s or variant angina) of coronary vasculature. Ertensi may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. Ertensi may be used alone, as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or adequate doses of beta-blockers.
How should I use Ertensi?
Use Ertensi as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Ertensi. Talk to your pharmacist if you have questions about this information.
- Take Ertensi by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Taking Ertensi at the same time each day will help you remember to take it.
- Continue to take Ertensi even if you feel well. Do not miss any doses.
- If you miss a dose of Ertensi, take it as soon as possible. If it has been more than 12 hours since you missed your last dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Ertensi.
Uses of Ertensi in details
This medication is used along with other treatment for certain blood vessel diseases (e.g., arteriosclerosis obliterans, Raynaud's disease, Buerger's disease, cerebrovascular insufficiency). It works by widening blood vessels to help increase blood flow (improve circulation) to certain parts of the body (e.g., hands/feet, brain). This effect may help to decrease symptoms such as cold hands and feet, numbness, tingling, and decreased memory or judgment.
How to use Ertensi
This medication is taken by mouth with or without food, usually 3 to 4 times daily or as directed by your doctor. Dosage is based on your medical condition and response to treatment.
Use this medication regularly to get the most benefit from it. To help you remember, take it at the same times each day.
Tell your doctor if your condition persists or worsens.
Ertensi description
Each 5-mg and 10-mg tablet contains Amlodipine besilate equivalent to Ertensi 5 mg and 10 mg, respectively.
Ertensi also contains the following excipients: Calcium hydrogen phosphate anhydrous, microcrystalline cellulose, magnesium stearate, sodium starch glycollate.
Ertensi besilate is the besilate salt of Ertensi, a long-acting calcium-channel blocker. It is 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulphonate. Its empirical formula is C20H25ClN2O5·C6H6O3S and has a molecular weight of 567.1.
Ertensi besilate is a white crystalline powder and is slightly soluble in water and sparingly soluble in ethanol.
Ertensi dosage
For both hypertension and angina, the usual initial dose is 5 mg Ertensi once daily, which may be increased to a maximum dose of 10 mg depending on the individual patient's response.
For patients with coronary artery disease, the recommended dosage range is 5 mg to 10 mg once daily. In clinical studies, the majority of patients required 10 mg once daily.
No dose adjustment of Ertensi is required upon concomitant administration of thiazide diuretics, beta-blockers, and ACE inhibitors.
Ertensi ODT: For Ertensi orodispersible tablets, the patient should place the tablet on the tongue and allow it to dissolve.
Elderly: Normal dosage regimens are recommended. Ertensi, used at similar doses in the elderly or younger patients, is equally well-tolerated.
Children: Safety and effectiveness of Ertensi in children have not been established.
Patients with Impaired Hepatic Function: See Precautions.
Patients with Renal Failure: Ertensi may be used at normal doses in patients with renal failure.
Changes in Ertensi plasma concentrations are not correlated with the degree of renal impairment. Ertensi is not dialyzable.
Ertensi interactions
See also:
What other drugs will affect Ertensi?
In vitro data in human plasma indicate that Ertensi has no effect on the protein-binding of drugs tested (digoxin, phenytoin, warfarin and indomethacin).
Special Studies: Effect of Other Agents on Ertensi:
Cimetidine: Co-administration of Ertensi with cimetidine did not alter the pharmacokinetics of Ertensi.
Grapefruit Juice: Co-administration of 240 mL of grapefruit juice with a single oral dose of Ertensi 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of Ertensi.
Antacid: Co-administration of antacid with a single dose of Ertensi had no significant effect on the pharmacokinetics of Ertensi.
Sildenafil: A single 100-mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of Ertensi. When Ertensi and sildenafil were used in combination, each agent independently exerted its own blood pressure-lowering effect.
Effect of Ertensi on Other Agents: Atorvastatin: Co-administration of multiple 10-mg doses of Ertensi with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
Digoxin: Co-administration of Ertensi with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.
Ethanol (alcohol): Single and multiple 10-mg doses of Ertensi had no significant effect on the pharmacokinetics of ethanol.
Warfarin: Co-administration of Ertensi with warfarin did not change the warfarin prothrombin response time.
In clinical trials, Ertensi has been safely administered with thiazide diuretics, β-blockers, ACE inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, NSAIDs, antibiotics and oral hypoglycemic drugs.
Drug/Laboratory Test Interactions: None known.
Ertensi side effects
See also:
What are the possible side effects of Ertensi?
The most common adverse effects of Ertensi besilate, similar to that of other calcium-channel blockers, are associated with its vasodilating effects are often lessened with continued use of the drug. Among them are flushing, headache disorders, dizziness and peripheral edema, the most common of which are edema and flushing which are due to the vasodilating effect of Ertensi.
Abdominal pain with cramps, fatigue, palpitations, tachycardia and nausea are less frequently experienced with the use of Ertensi.
Other adverse effects associated with the use of Ertensi include increased micturition, eye pain and other visual disturbances, mental or mood changes eg, depression, anxiety or nervousness, decreased sexual ability/desire, constipation and fainting.
At the start of the treatment, a paradoxical increase in ischemic chest pain may be experienced. In some patients, cerebral or myocardial ischemia or transient blindness caused by excessive fall in blood pressure occur. Ertensi, in 1 study was found to induce gingival overgrowth.
Hypersensitivity reactions to Ertensi may occur leading to rashes, including erythema multiforme, fever and abnormal liver functions eg, cholestasis. Other symptoms of allergic reactions are itching, swelling, severe dizziness and trouble breathing.
Ertensi contraindications
See also:
What is the most important information I should know about Ertensi?
Before taking Ertensi, tell your doctor if you have congestive heart failure or liver disease.
Drinking alcohol can further lower your blood pressure and may increase certain side effects of Ertensi.
If you are being treated for high blood pressure, keep using this medication even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.
Ertensi is only part of a complete program of treatment that may also include diet, exercise, weight control, and other medications. Follow your diet, medication, and exercise routines very closely.
Tell your doctor about all other heart or blood pressure medications you are taking.
Your chest pain may become worse when you first start taking Ertensi or when your dose is increased. Call your doctor if your chest pain is severe or ongoing.
Active ingredient matches for Ertensi:
Amlodipine in Indonesia.
Amlodipine besylate in Indonesia.
| Unit description / dosage (Manufacturer) | Price, USD |
| Ertensi 5 mg x 30's | $ 14.69 |
List of Ertensi substitutes (brand and generic names): | |
| Eroamlo (Vietnam) | |
| Eroamlo 10 mg x 3 Blister x 10 Tablet | |
| Esamlo (India) | |
| Esamlo 2.5mg TAB / 100 (Orchid (Cardiovascular)) | $ 0.25 |
| Esamlo 5mg TAB / 10 (Orchid (Cardiovascular)) | $ 0.46 |
| 2.5 mg x 100's (Orchid (Cardiovascular)) | $ 0.25 |
| 5 mg x 10's (Orchid (Cardiovascular)) | $ 0.46 |
| ESAMLO 2.5MG TABLET 1 strip / 10 tablets each (Orchid (Cardiovascular)) | $ 0.31 |
| ESAMLO 5MG TABLET 1 strip / 10 tablets each (Orchid (Cardiovascular)) | $ 0.58 |
| ESAMLO tab 2.5 mg x 10's (Orchid (Cardiovascular)) | $ 0.25 |
| ESAMLO tab 5 mg x 10's (Orchid (Cardiovascular)) | $ 0.46 |
| Escordi Cor (Russian Federation) | |
| Tablet; Oral; Amlodipine Besylate 2.5 mg (Actavis Pharma) | |
| Tablet; Oral; Amlodipine Besylate 5 mg (Actavis Pharma) | |
| Eslo-RIL (India) | |
| Eslo-RIL S-amlodipine besylate 2.5 mg, Ramipril 2.5 mg. TAB / 10 (Zuventus) | $ 0.92 |
| 10's (Zuventus) | $ 0.92 |
| Eslo-Ril - Amlodipine Bestylate2.5mg, Ramipril 2.5mg TAB / 10 (Zuventus) | $ 0.92 |
| ESLO-RIL tab 10's (Zuventus) | $ 0.92 |
| Eslo-Ril - Amlodipine Bestylate2.5mg, Ramipril 2.5mg TAB / 10 (Zuventus) | $ 0.92 |
| Espin-AT (India) | |
| Espin-AT S-amlodipine 2.5 mg, Atenolol50 mg. TAB / 10 (Intas) | $ 0.12 |
| Espin-AT S-amlodipine 2.5 mg, Atenolol50 mg TAB / 10 (Intas) | $ 0.12 |
| 10's (Intas) | $ 0.12 |
| ESPIN-AT 50 MG/2.5 MG TABLET 1 strip / 10 tablets each (Intas) | $ 0.52 |
| ESPIN-AT tab 10's (Intas) | $ 0.12 |
| Espin-LT (India) | |
| Espin-LT S-amlodipine 2.5 mg, Losartan50 mg. TAB / 10 (Intas) | $ 0.87 |
| 10's (Intas) | $ 0.87 |
| ESPIN-LT 50 MG/2.5 MG TABLET 1 strip / 10 tablets each (Intas) | $ 1.31 |
| ESPIN-LT tab 10's (Intas) | $ 0.87 |
| Ethivask (Indonesia) | |
| Ethivask 5 mg x 3 x 10's | $ 7.44 |
| Ethivask 10 mg x 3 x 10's | |
| Eucoran (Colombia, Peru) | |
| Europine | |
| Europine 5mg TAB / 10 | |
| Evangio (Greece, Malta) | |
| Evasc (South Korea) | |
| EXLODEP | |
| EXLODEP 5MG TABLET 1 strip / 20 tablets each (Olcare (Excare)) | $ 0.33 |
| EXLODEP tab 5 mg x 10's (Olcare (Excare)) | $ 0.24 |
| Fabocef (Argentina) | |
| Fada Amlodipina (Argentina) | |
| Famodip (Vietnam) | |
| Famodip 5 mg x 1 Box | |
| Farlod (Pakistan) | |
| Finacal 10 (Peru) | |
| Finacal 5 (Peru) | |
| Finamlox (Poland) | |
| Finevask (Indonesia) | |
| Fixodip (Turkey) | |
See 4161 substitutes for Ertensi | |
References
- PubChem. "amlodipine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "amlodipine". http://www.drugbank.ca/drugs/DB00381 (accessed September 17, 2018).
- MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Ertensi are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ertensi. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
